Page last updated: 2024-11-03

procarbazine and Diffuse Parenchymal Lung Disease

procarbazine has been researched along with Diffuse Parenchymal Lung Disease in 1 studies

Procarbazine: An antineoplastic agent used primarily in combination with mechlorethamine, vincristine, and prednisone (the MOPP protocol) in the treatment of Hodgkin's disease.
procarbazine : A benzamide obtained by formal condensation of the carboxy group of 4-[(2-methylhydrazino)methyl]benzoic acid with the amino group of isopropylamine. An antineoplastic chemotherapy drug used for treatment of Hodgkin's lymphoma. Metabolism yields azo-procarbazine and hydrogen peroxide, which results in the breaking of DNA strands.

Research

Studies (1)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (100.00)18.2507
2000's0 (0.00)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Aisenberg, AC1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Evaluation of Late Treatment Effects in Long-Term Survivors of Hodgkin's Disease Previously Treated at NIH: A Multi-Institutional Trial[NCT00924131]157 participants (Anticipated)Observational2009-04-17Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Reviews

1 review available for procarbazine and Diffuse Parenchymal Lung Disease

ArticleYear
Problems in Hodgkin's disease management.
    Blood, 1999, Feb-01, Volume: 93, Issue:3

    Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Bleomycin; Bone Marrow Transplant

1999